Incidental thyroid carcinoma in benign thyroid diseases

2013 ◽  
Vol 39 (9) ◽  
pp. S55
Author(s):  
S. Dhimolea ◽  
F. Rulli ◽  
M.I. Bellini ◽  
P. Gentileschi ◽  
F.M. Carrano ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Thyroid Diseases ◽  
Incidental Thyroid Carcinoma ◽  
Benign Thyroid

INCIDENTAL THYROID CARCINOMA IN A LARGE SERIES OF CONSECUTIVE PATIENTS OPERATED ON FOR BENIGN THYROID DISEASE

2006 ◽  
Vol 76 (3) ◽  
pp. 123-126 ◽  
Author(s):  
Paolo Miccoli ◽  
Michele N. Minuto ◽  
David Galleri ◽  
Jacopo D'Agostino ◽  
Fulvio Basolo ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Thyroid Disease ◽  
Large Series ◽  
Benign Thyroid Disease ◽  
Incidental Thyroid Carcinoma ◽  
Benign Thyroid

scholarly journals Significance of Interleukin-6 in Papillary Thyroid Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Toral P. Kobawala ◽  
Trupti I. Trivedi ◽  
Kinjal K. Gajjar ◽  
Darshita H. Patel ◽  
Girish H. Patel ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Mrna Expression ◽  
Cancer Progression ◽  
Primary Tumour ◽  
Thyroid Diseases ◽  
Papillary Thyroid ◽  
Healthy Individuals ◽  
Poor Overall Survival ◽  
Benign Thyroid

This study sought to reveal the significance of IL-6 in papillary thyroid carcinoma by determining its circulating levels, tumoral protein, and mRNA expressions. As compared to the healthy individuals, serum IL-6 was significantly higher in patients with benign thyroid diseases and PTC. Further, its level was significantly higher in PTC patients as compared to patients with benign thyroid diseases. ROC curves also confirmed a good discriminatory efficacy of serum IL-6 between healthy individuals and patients with benign thyroid diseases and PTC. The circulating IL-6 was significantly associated with poor overall survival in PTC patients. IL-6 immunoreactivity was significantly high in PTC patients as compared to the benign thyroid disease patients. Significantly higher IL-6 mRNA expression was also observed in the primary tumour tissues of PTC patients than the adjacent normal tissues. The protein expression of IL-6 at both the circulating and tissue level correlated with disease aggressiveness in PTC patients. Moreover, a significant positive correlation was observed between the IL-6 protein and mRNA expression in the primary tumours of PTC patients. Finally in conclusion, IL-6 has an important role in thyroid cancer progression. Thus targeting IL-6 signalling can help in clinical management of thyroid carcinoma patients.

THYROID CARCINOMA IN BENIGN THYROID DISEASES An Analysis from Minute Carcinoma

1985 ◽  
Vol 35 (4) ◽  
pp. 781-788
Author(s):  
Hiroto Yamashita ◽  
Iwao Nakayama ◽  
Shiro Noguchi ◽  
Nobuo Murakami ◽  
Akira Moeiuchi ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Thyroid Diseases ◽  
Benign Thyroid

Incidental Carcinoma in Multinodular Goiter: Risk Factors

2011 ◽  
Vol 77 (11) ◽  
pp. 1553-1558 ◽  
Author(s):  
Ivan Botrugno ◽  
Federico Lovisetto ◽  
Lorenzo Cobianchi ◽  
Sandro Zonta ◽  
Catherine Klersy ◽  
...  
Keyword(s):  
Risk Factors ◽  
Family History ◽  
Thyroid Carcinoma ◽  
Multinodular Goiter ◽  
Endemic Goiter ◽  
Thyroid Diseases ◽  
Personal History ◽  
X Rays ◽  
Incidental Thyroid Carcinoma ◽  
History Of

The aim of the study was to analyze the frequency of incidental thyroid carcinoma (unknown tumor smaller than or equal to 10 mm) in a consecutive series of 462 total thyroidectomies for multinodular goiter and to investigate the clinical risk factors for this type of malignancy. A retrospective, single-center study of outcome data collected from patients with preoperative diagnosis of multinodular goiter who underwent total thyroidectomy at the General Surgery Unit of Pavia (Italy) between January 2000 and December 2008 was performed. Possible risk factors for malignancy were: gender, age, time of evolution of goiter, presence of a dominant nodule in multinodular goiter, hyperthyroidism, history of radiation to the neck, residence in an area of endemic goiter, prior thyroid surgery, calcifications in the goiter detected by neck ultrasound or chest X-rays, and a family history of thyroid diseases. In a 9-year period, 462 patients underwent total thyroidectomy. We found 41 cases of incidental thyroid carcinoma; the most common histopathological type was papillary. The multivariable analysis demonstrated that the clinical variables associated with occult carcinoma were a personal history of radiation therapy to the neck, the presence of calcifications detected by ultrasound or neck X-rays, and a family history of thyroid diseases; residence in an area of endemic goiter was a protective factor. A personal history of radiation to the neck, detection of calcifications by ultrasound or by neck X-rays, and a family history of thyroid diseases should be considered clinical risk factors for malignancy in multinodular goiter.

scholarly journals Incidental Thyroid Carcinoma in Benign Thyroid Disease: A Cohort Study

2018 ◽  
Vol 10 (3) ◽  
pp. 154-156
Author(s):  
Ranil Fernando ◽  
Diluka Pinto ◽  
Nalinda Munasinghe ◽  
Pramod C Chandrasinghe
Keyword(s):  
Cohort Study ◽  
Thyroid Carcinoma ◽  
Thyroid Disease ◽  
Benign Thyroid Disease ◽  
Incidental Thyroid Carcinoma ◽  
Benign Thyroid

scholarly journals Significance of TNF-αand the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-17 ◽  
Author(s):  
Toral P. Kobawala ◽  
Trupti I. Trivedi ◽  
Kinjal K. Gajjar ◽  
Darshita H. Patel ◽  
Girish H. Patel ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Adhesion Molecules ◽  
Serum Levels ◽  
Thyroid Diseases ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Aggressive Tumor ◽  
Circulating Levels ◽  
Benign Thyroid

Circulating levels of TNF-αand the adhesion molecules L-Selectin and VCAM-1 as well as their expression in the primary tumors of patients with benign thyroid diseases and papillary thyroid carcinoma (PTC) have been determined in this study. The serum levels of TNF-α, L-Selectin, and VCAM-1 were significantly higher in patients with both benign thyroid diseases and PTC as compared to the healthy individuals. However, the levels of only TNF-αand L-Selectin, and not VCAM-1, were significantly higher in patients with PTC in comparison to those observed in patients with benign thyroid diseases. Further the expression of TNF-αand L-Selectin was also significantly higher in the primary tumors of PTC patients, relative to the benign thyroid diseases. The expression of L-Selectin and VCAM-1 significantly correlated with aggressive tumor behavior. In PTC patients, the circulating TNF-αlevels significantly positively correlated with the levels of L-Selectin, while TNF-αimmunoreactivity was significantly associated with VCAM-1 expression. Serum TNF-αwas found to be a significant prognosticator for OS in PTC patients. Overall the results signify that the interaction between TNF-αand the adhesion molecules may have a role in thyroid carcinogenesis and understanding this complexity may offer potential therapeutic targets for better management of thyroid cancer.

Guideline for radioiodine therapy for benign thyroid diseases (version 3)

2004 ◽  
Vol 43 (06) ◽  
pp. 217-220 ◽  
Author(s):  
J. Dressler ◽  
F. Grünwald ◽  
B. Leisner ◽  
E. Moser ◽  
Chr. Reiners ◽  
...  
Keyword(s):  
Radioiodine Therapy ◽  
Thyroid Volume ◽  
Thyroid Diseases ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Co Morbidity ◽  
History Of ◽  
Individual Decisions ◽  
Prophylactic Use ◽  
Benign Thyroid

SummaryThe version 3 of the guideline for radioiodine therapy for benign thyroid diseases presents first of all a revision of the version 2. The chapter indication for radioiodine therapy, surgical treatment or antithyroid drugs bases on an interdisciplinary consensus. The manifold criteria for decision making consider the entity of thyroid disease (autonomy, Graves’ disease, goitre, goitre recurrence), the thyroid volume, suspicion of malignancy, cystic nodules, risk of surgery and co-morbidity, history of subtotal thyroidectomy, persistent or recurrent thyrotoxicosis caused by Graves’ disease including known risk factors for relapse, compression of the trachea caused by goitre, requirement of direct therapeutic effect as well as the patient’s preference. Because often some of these criteria are relevant, the guideline offers the necessary flexibility for individual decisions. Further topics are patients’ preparation, counseling, dosage concepts, procedural details, results, side effects and follow-up care. The prophylactic use of glucocorticoids during radioiodine therapy in patients without preexisting ophthalmopathy as well as dosage and duration of glucocorticoid medication in patients with preexisting ophthalmopathy need to be clarified in further studies. The pragmatic recommendations for the combined use of radioiodine and glucocorticoids remained unchanged in the 3rd version.

Incidental Thyroid Carcinoma on Parathyroid Imaging

2002 ◽  
Vol 27 (9) ◽  
pp. 658-659 ◽  
Author(s):  
MICHAEL E. SPIETH ◽  
GERALD M. MULLIGAN ◽  
THANHCUONG NGUYEN ◽  
DARCY L. KASNER
Keyword(s):  
Thyroid Carcinoma ◽  
Incidental Thyroid Carcinoma ◽  
Parathyroid Imaging
Sign in / Sign up

Export Citation Format

Share Document